Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor

Journal of Clinical Oncology

Volumn 15, Issue 2, 1997, Pages 781-789

  Berlin, J ^a   Tutsch, K D ^a   Hutson, P ^a   Cleary, J ^a   Rago, R P ^a   Arzoomanian, R Z ^a   Alberti, D ^a   Feierabend, C ^a   Wilding, G ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE;

ADULT; AGED; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CALCIUM TRANSPORT; CANCER CELL; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; FATIGUE; FEMALE; GROWTH INHIBITION; HUMAN; MALE; NAUSEA; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VOMITING;

EID: 0031015772     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.2.781     Document Type: Article

References (17)

1. Kohn EC, Liotta LA: L651582: A novel antiproliferative and antimetastasis agent. J Natl Cancer Inst 82:54-60, 1990
2. Kohn EC, Sandeen MA, Liotta LA: In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium arachidonate, and inositol phosphates. Cancer Res 52:3208-3212, 1992
3. Hupe DJ, Behrens ND, Baltz R: Anti-proliferative activity of L-651582 correlates with calcium-mediated regulation of nucleotide metabolism at phosphoribosyl pyrophosphate synthetase. J Cell Physiol 144:457-466, 1990
4. Hupe DJ, Boltz R, Cohen CJ, et al.: The inhibition of receptor-mediated and voltage-dependent calcium entry by the antiproliferative L-651,582. J Biol Chem 266:10136-10142, 1991
5. Felder CC, Ma AL, Liotta LA, et al.: The antiproliferative and antimetastatic compound L651582 inhibits muscarinic acetylcholine receptor-stimulated calcium influx and arachidonic acid release. J Pharm Exp Ther 257:967-971, 1991
6. Kohn EC, Felder CC, Jacobs W, et al.: Structure-function analysis of signal and growth inhibition by carboxyamido-triazole, CAI. Cancer Res 54:935-942, 1994
7. Kohn EC, Alessandro R, Spoonster J, et al.: Angiogenesis: Role of calcium-mediated signal transduction. Proc Natl Acad Sci USA 92:1307-1311, 1995
8. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6, 1990
9. Kohn EC, Jacobs W, Kim YS, et al.: Calcium influx modulates expression of matrix metalloproteinase-2 (72-kDa type IV collagenase, gelatinase A). J Biol Chem 269:21505-21511, 1994
10. Buick AR, Doig MV, Jeal SC, et al.: Method validation in the bioanalytical laboratory. J Pharmaceut Biomed Anal 8:629-637, 1990
11. Gibaldi M, Perrier D: Pharmacokinetics (ed 2). New York, NY, Dekker, 1982
12. Ludden LK, Strong JM, Kohn EC, et al.: Similarity of metabolism for CAI (NSC 609974) in human liver tissue in vitro and in humans in vivo. Clin Cancer Res 1:399-405, 1995
13. Kohn E, Reed E, Sarosy G, et al.: Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res 56:569-573, 1996
14. Cleeland CS, Gonin R, Hatfield AK, et al.: Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 330:592-596, 1994
15. Cleeland CS, Ryan KM: Pain assessment: global use of the brief pain inventory. Ann Acad Med Singapore. 23:129-138, 1994
16. Serlin RC, Mendoza TR, Nakamura Y, et al.: When is pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61:277-284, 1995
17. Figg WD, Cole KA, Reed E, et al.: Pharmacokinetics of orally administered carboxyamido-triazole, an inhibitor of calcium-mediated signal transduction. Clin Cancer Res 1:797-803, 1995